Volatile organic compounds analysis optimization and biomarker discovery in urine of Non-Hodgkin lymphoma patients before and during chemotherapy

• Published in: Microchemical journal Vol. 159; p. 105479
• Main Authors: de Sousa Mesquita, Alessandra, Zamora-Obando, Hans Rolando, Neves dos Santos, Fábio, Schmidt-Filho, Jayr, Cordeiro de Lima, Vladmir, D'Almeida Costa, Felipe, Piana de Andrade, Victor, Nogueira Eberlin, Marcos, Colnaghi Simionato, Ana Valéria
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.12.2020
• Subjects: Biomarkers; Central composite design; GC–MS; HS-SPME; Non-hodgkin lymphoma; Volatile organic compounds; QCs; UDP; VOCs; GC–MS; IPI; Central composite design; HL; CCD; COX-1; HS; Volatile organic compounds; HS-SMPE; NHL; PI3K; HS-SPME; Non-hodgkin lymphoma; NaCl; Biomarkers; MF; CAR/DVB/PDMS
• ISSN: 0026-265X
• DOI: 10.1016/j.microc.2020.105479

[Display omitted] •Volatile organic compounds from biofluids have been investigated by HS-SPME GC-MS.•An untargeted metabolomics approach has been used.•Central Composite Design has been applied for sample extraction optimization.•Urine samples from healthy and Non-Hodgkin Lymphoma’ individuals have been analyzed.•Metabolomic data treatment has shown putative diagnostic and prognostic biomarkers. The Non-Hodgkin's lymphoma (NHL) is a severe and common neoplasm generated by metabolic changes due to cells mutations. Its prognostic or diagnosis seems therefore viable by monitoring metabolites produced and secreted into biological fluids or tissues. Hence, we used an untargeted metabolomics approach to evaluate if the profiles of volatile organic compounds (VOCs) present in urine would serve to Non-Hodgkin's lymphoma (NHL) prognostic or diagnostic. Headspace solid-phase microextraction (HS-SPME) was optimized and applied to pools of urine or serum samples from healthy patients after optimization using a Central Composite Design (CCD), followed by gas chromatography coupled to mass spectrometry (GC–MS) analysis. CCD factorial design 23 and the response surfaces indicated the optimized extraction parameters. Individual urine samples from healthy and diseased subjects were prepared and analyzed by the optimized method, and a thorough statistical analysis revealed several metabolites as potential biomarkers for NHL as well as able to describe the patient's metabolic profile before each chemotherapy cycle. This approach seems promising in contributing to the prognosis and choice of appropriate treatment of NHL for each individual.